Persistent Systems has announced a collaboration with NVIDIA to enhance AI-powered solutions for the Healthcare and Life Sciences industry. This partnership aims to accelerate computational drug discovery and improve research outcomes through the use of Generative AI and advanced analytics.
The initiative will leverage NVIDIA’s AI Enterprise platform to support specialised Life Sciences R&D applications, including preclinical research. Persistent’s new Generative Molecules and Virtual Screening solution, powered by NVIDIA’s BioNeMo platform, will facilitate high-fidelity molecular simulations and virtual screenings. This approach aims to streamline drug discovery workflows and improve the efficiency of early-stage research.
Persistent plans to utilise NVIDIA Nemotron open models to enhance its solution further. The company will also employ NVIDIA accelerated computing resources to develop scalable, production-grade AI applications. This infrastructure will support real-time scientific decision-making in regulated research environments.
Ganesh Nathella, Executive Vice President at Persistent, highlighted the importance of speeding up therapy discovery processes, while John Fanelli, Vice President at NVIDIA, emphasised the shift towards AI-driven research in the industry.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).